

Chronic Idiopathic Urticaria - Pipeline Insight, 2021

https://marketpublishers.com/r/CCE88975A75EEN.html

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: CCE88975A75EEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Chronic Idiopathic Urticaria - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Idiopathic Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Idiopathic Urticaria Understanding

Chronic Idiopathic Urticaria: Overview

Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ? six weeks. CU can be further divided into two different subtypes, namely, chronic idiopathic urticaria (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder. Chronic spontaneous urticaria refers to chronic urticaria that has no specific cause or trigger. Weals are present on most days of the week for 6 weeks or more. Chronic spontaneous urticaria was previously referred to as chronic idiopathic urticaria. This term is no longer used as many cases have an autoimmune basis.



'Chronic Idiopathic Urticaria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Idiopathic Urticaria pipeline landscape is provided which includes the disease overview and Chronic Idiopathic Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Idiopathic Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Idiopathic Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Idiopathic Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Idiopathic Urticaria.

Chronic Idiopathic Urticaria Emerging Drugs Chapters

This segment of the Chronic Idiopathic Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Idiopathic Urticaria Emerging Drugs

Ligelizumab: Novartis

Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/Fc?RI pathway, a key driver of the inflammatory process in CSU. Ligelizumab (QGE031) had received FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU). Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate



response to H1-antihistamines

Dupilumab: Regeneron

It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is in phase III stage of development to treat Chronic Spontaneous Urticaria.

Tezepelumab: Amgen

Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults. Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma

Further product details are provided in the report......

Chronic Idiopathic Urticaria: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Idiopathic Urticaria drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Idiopathic Urticaria

There are approx. 20+ key companies which are developing the therapies for Chronic Idiopathic Urticaria. The companies which have their Chronic Idiopathic Urticaria drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Phases



DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)			
Mid-stage products (Phase II)			
Early-stage product (Phase I) along with the details of			
Pre-clinical and Discovery stage candidates			
Discontinued & Inactive candidates			
Route of Administration			
Chronic Idiopathic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as			
Oral			
Parenteral			
intravenous			
Subcutaneous			
Topical.			
Molecule Type			
Products have been categorized under various Molecule types such as			
Monoclonal Antibody			
Peptides			



Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Idiopathic Urticaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Idiopathic Urticaria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Idiopathic Urticaria drugs.
Chronic Idiopathic Urticaria Report Insights
Chronic Idiopathic Urticaria Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Chronic Idiopathic Urticaria Report Assessment

Chronic Idiopathic Urticaria - Pipeline Insight, 2021

Pipeline Product Profiles



Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Chronic Idiopathic Urticaria drugs?
How many Chronic Idiopathic Urticaria drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Idiopathic Urticaria?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Idiopathic Urticaria therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Idiopathic Urticaria and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Novartis

Regeneron



Amgen				
AstraZeneca				
United BioPharma				
Celltrion				
Celldex Therapeutics				
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.				
Gilead Sciences				
Stero Biotechs Ltd.				
UCB Biopharma SRL				
GlaxoSmithKline				
UBP Greater China (Shanghai) Co., Ltd				
Genentech				
Kiniksa Pharmaceuticals, Ltd.				
Key Products				
Ligelizumab				
Dupilumab				
Tezepelumab				
Benralizumab				
UB-221				





CT-P39
CDX-0159
SYN008
Tirabrutinib

UCB8600

Nucala

UB-221

GDC-0853

KPL-716



Contents

Introduction

Executive Summary

Chronic Idiopathic Urticaria: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Ligelizumab: Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Tezepelumab: Amgen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

UCB8600: UCB Pharma

Product Description

Research and Development

Product Development Activities



Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Chronic Idiopathic Urticaria Key Companies

Chronic Idiopathic Urticaria Key Products

Chronic Idiopathic Urticaria- Unmet Needs

Chronic Idiopathic Urticaria- Market Drivers and Barriers

Chronic Idiopathic Urticaria- Future Perspectives and Conclusion

Chronic Idiopathic Urticaria Analyst Views

Chronic Idiopathic Urticaria Key Companies

Appendix



List Of Tables

LIST OF TABLES

Table 1 Total Pro	ducts for	Chronic	Idiopathic	Urticaria
-------------------	-----------	---------	------------	-----------

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products



List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Chronic Idiopathic Urtic	aria
--	------

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products



I would like to order

Product name: Chronic Idiopathic Urticaria - Pipeline Insight, 2021

Product link: https://marketpublishers.com/r/CCE88975A75EEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CCE88975A75EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970